Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma

समान संसाधन

• Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
  द्वारा: Gu, Chunyan, और अन्य
  प्रकाशित: (2018)
• Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome
  द्वारा: Gu, Chunyan, और अन्य
  प्रकाशित: (2018)
• FOXM1 is a therapeutic target for high-risk multiple myeloma
  द्वारा: Gu, Chunyan, और अन्य
  प्रकाशित: (2015)
• Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma
  द्वारा: Rosean, Timothy R., और अन्य
  प्रकाशित: (2014)
• NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma
  द्वारा: Yang, Ye, और अन्य
  प्रकाशित: (2014)